Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.44233 EPS, expectations were $-1.2. Axsome Therapeutics, Inc.
Axsome Therapeutics Inc. (AXSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 1,304,721 | $104,116,736 | +31% | 2.98% |
| 2. | Citadel Investment Group Ken Griffin | 1,143,644 | $91,262,792 | +6% | 0.01% |
| 3. | Perceptive Advisors Joseph Edelman | 1,105,341 | $88,206,212 | +7% | 1.53% |
| 4. | RA Capital Management Peter Kolchinsky | 1,000,000 | $79,800,000 | 1.01% | |
| 5. | Millennium Management Israel Englander | 741,518 | $59,173,136 | -19% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.30 | 3,950 | Director | 120,756 | 2021-11-19 | Filing | |
| $35.20 | 142 | Officer | 142 | 2021-11-18 | Filing | |
| $34.30 | 145 | Officer | 145 | 2021-11-18 | Filing | |
| $35.43 | 141 | Officer | 201 | 2021-11-18 | Filing | |
| $35.50 | 527 | Officer | 41,789 | 2021-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $77.24 | 24,662 | 0 | 2024-04-01 | Filing | ||
| $71.61 | 2,347 | 120,756 | 2024-03-15 | Filing | ||
| $69.70 | 16,976 | 120,756 | 2024-03-14 | Filing | ||
| $69.70 | 13,000 | 120,756 | 2024-03-14 | Filing | ||
| $75.18 | 18,572 | Director | 403,856 | 2023-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,489,596 | $357,326,946 | 5.58% | |
| 2. | 3,696,766 | $294,225,606 | 0% | |
| 3. | 3,239,746 | $257,851,385 | 0% | |
| 4. | 2,360,077 | $187,838,528 | 19.84% | |
| 5. | 924,190 | $73,556,282 | 0% |
News See All
Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets
In this article, we will discuss the 10 stocks whose price targets were recently raised by analysts.
11 Oversold NASDAQ Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now.
11 Oversold Healthcare Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript
Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-2.08 EPS, expectations were $-1.21. Axsome Therapeutics, Inc.
11 Best Upside Stocks To Buy Right Now
The art of buying shares on the market has always gone hand in hand with share price analysis. A share price, in its simplest form, is the market's estimate of the company's future.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Axsome Therapeutics Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
30 Happiest Countries in the World
In this piece, we will take a look at the 30 happiest countries in the world.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to the Axsome Therapeutics Second Quarter Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2023 Earnings Call Transcript
Operator: Hello and welcome to the Axsome Therapeutics First Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Billionaire Hedge Funds
